Could a gallium pill reach brain tumors? tiny trial aims to find out

NCT ID NCT07515924

Not yet recruiting Knowledge-focused Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial will test whether an oral drug called gallium maltolate can reach brain tumors in people with recurrent glioblastoma. Eight participants will take the drug for about two weeks before surgery, and researchers will measure gallium levels in the removed tumor tissue. The goal is not to treat the cancer but to see if the drug penetrates the brain, which could guide future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gallium maltolate
What this could lead to: If successful, this could show that gallium maltolate reaches brain tumors, pointing toward a potential new treatment for glioblastoma.
What could go wrong: This is a very early Phase 0 trial with only 8 participants. It is designed to measure drug levels, not to test effectiveness or safety. The drug may not reach therapeutic concentrations or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Froedtert & the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.